Livingstone Health Holdings (PRH) Fair Value & Analysis
Healthcare · SG · Market cap 16.4M SGD
Fair value as of: Jul 4, 2026
From 21 valuation models · updated yesterday
Share price −7.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0200 SGD – 0.0330 SGD · the 0.0260 SGD price screens above the 0.0218 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Livingstone Health Holdings (PRH) currently trades at 0.0260 SGD, while our model-based Fair Value estimate is 0.0218 SGD — implying the stock looks roughly 16.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Livingstone Health Holdings generated revenue of 29.3M SGD at a net margin of 0.8%. Revenue grew 1.9% year over year. It earns a return on equity of -10.5%. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Livingstone Health Holdings Limited, an investment holding company, provides medical treatment and consultancy services in Singapore. It operates through three segments: Specialist Healthcare, Primary Healthcare, and Others. The Specialist Healthcare segment offers medical services in anaesthesiology and pain management; orthopaedic surgery; dermatology; and internal medicine fields, as well as endocrinology services. The Primary Healthcare segment is involved in the provision of vaccination and general medicine services; and the management of general acute conditions, such as respiratory/gastrointestinal infections, musculoskeletal complaints, headaches, and dermatological conditions, as well as chronic conditions comprising diabetes, hypertension, dyslipidaemia, and asthma. The Other segment provides aesthetics and wellness, podiatry, nerve testing, and consultancy function solutions. This segment also engages in the management of healthcare solutions and provision of management …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Livingstone Health Holdings reported revenue of 29.3M SGD in FY2025 versus 34.1M SGD in FY2021, a compound −3.8%/yr. Reported net income was 223K SGD in FY2025, compounding −47.9%/yr from FY2021.
Is PRH fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Livingstone Health Holdings (PRH) undervalued?
What is the fair value of PRH?
What is the quality score of PRH?
What is the revenue of Livingstone Health Holdings (PRH)?
What is the net profit margin of PRH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.